Smarter Solutions.
Better Outcomes. Better Health.

Simple, innovative and affordable diagnostic solutions

We create innovative, patient focused, lab-accurate diagnostics that are transforming community based healthcare. Our products are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, care homes and workplaces to screen, diagnose, and monitor wellness as well as disease.

Our products are next-generation solutions that use cloud-based technology and data to develop supported self-care plans to improve individual health and system-wide outcomes. We put all our efforts and experience into creating diagnostic solutions that are smart, accessible and affordable.

Partnership and expertise

MEET OUR LEADERS

Veronique Ameye EMBA

Chief Executive Officer and General Counsel

Dorian LeBlanc

Chief Financial Officer

David Walton

Chief Commercial Officer

Roche acquired select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology as part of a pre-packaged UK administration sale, not the shares of the Cayman Islands entity LumiraDx Limited. Questions relating to the assignment of the transaction proceeds to LumiraDx 's creditors should therefore be directed to the administrator, FTI (https://www.fticonsulting.com/en/creditors/lumira-dx).

LumiraDx Limited is being wound up in accordance with the Cayman Islands' Companies Act. Any stakeholders of LumiraDx Limited, including holders of the company’s equity or debt securities, may contact the joint official liquidators via the following correspondence address: LumiraDxJOLs@uk.gt.com.

Join us and make an impact across the globe

Explore careers

Related publications

NewsLink

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances. LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas. By integrating LumiraDx, Roche will further its ambition to deliver decentralised solutions that expand global access to testing in primary care settings worldwide.
View Link

White PaperPDF

St Malo Evaluation of LumiraDx Analyzer for decentralized CRP testing
The availability of CRP blood testing is important in emergency medicine to ensure the relevance of the antibiotic therapy prescription. Its use in decentralized laboratory testing requires comparing the methods to the laboratory reference technique. The LumiraDx TM CRP test is a microfluidic immunoassay to quantify CRP levels in whole blood and plasma samples in 4 minutes.
View Link

White PaperPDF

St Malo: How the health crisis changed our approach to decentralized laboratory testing
The global SARS-COV2 pandemic has profoundly changed the organization of healthcare services and regional hospital groups. Delocalized laboratory testing has quickly adapted to three challenges. It was first necessary to respond to the growing demand for ABG testing for “ephemeral resuscitation” and the management of respiratory distress. Then came the time for mass viral detection. Unlike the Rapid Diagnostic Test (RDT), decentralized laboratory testing could offer reliable, rapid tests in under 5 minutes, that were traceable and that met the quality criteria (Rapid and Connectable Point-of-Care COVID-19 Coulon et al. Diagnostics 2023,13,3508). Finally, the resurgence of COVID epidemic waves with influenza or RSV epidemics required the development of combined antigen tests.
View Link
Want to see more?